Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.52 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.52 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.52 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.52 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192165 | 0.92 | ALK (0.43) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL2130483 | 0.84 | CDK5 (0.55) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL2600368 | 0.82 | HCRTR1 (0.44) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL941764 | 0.81 | CDK1 (0.48) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL4060329 | 0.81 | CCNE1 (0.46) | CDK2GSK3BCDK5CDK1HCRTR1 | |
| SCHEMBL4059965 | 0.79 | CDK1 (0.49) | DYRK3CDK2GSK3BCDK5PIM3 | |
| Hydrochloric Acid SCHEMBL27601574 | 0.79 | DYRK3 (0.47) | DYRK3CDK2GSK3BCDK5PIM3 | |
| Hydrochloric Acid SCHEMBL4060348 | 0.79 | CDK1 (0.49) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL4026378 | 0.77 | CDK1 (0.54) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL477974 | 0.77 | DYRK3 (0.58) | DYRK3CDK2GSK3BCDK5PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| US-20120101132-A1 | New Substituted Oxindole Derivative | CLAESSON MARTINA (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101132-A1 | New Substituted Oxindole Derivative | CLAESSON MARTINA (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20090291982-A1 | New Substituted Oxindole Derivative 352 | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | disclosed |
| US-20090291982-A1 | New Substituted Oxindole Derivative 352 | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | disclosed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291982-A1 | New Substituted Oxindole Derivative 352 | PYGL, GSK3A, GSK3B | DYRK3 279/4885CDK2 281/4885GSK3B 3/4885 |
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | DYRK3 4809/4885CDK2 245/4885GSK3B 1261/4885 |
| US-20120101132-A1 | New Substituted Oxindole Derivative | PYGL, GSK3A, GSK3B | DYRK3 426/4885CDK2 377/4885GSK3B 3/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | DYRK3 4783/4885CDK2 655/4885GSK3B 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.